FRANKFURT (Reuters) - Genzyme agreed to buy key rights to the leukemia drug Campath, also tested as a multiple sclerosis (MS) treatment, from its German development partner Bayer, the two companies ...

Bayer stands to earn up to $1.9 billion dependent on approval and sales achievements. Genzyme is taking over worldwide rights from Bayer HealthCare covering Campath® (alemtuzumab), which is approved ...

The UK's National Institute for Health and Care Excellence (NICE) on 6 December 2013 issued a final appraisal determination (FAD) recommending reimbursement for Genzyme's multiple sclerosis drug ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Less than two months after Genzyme’s newest drug to treat ...

Genzyme, the biotechnology company with significant operations in MetroWest, reported positive results for a Phase-III test of its alemtuzumab drug for treatment of multiple sclerosis. The test found ...

GAIL J. MADERIS is President of Genzyme Molecular Oncology. With more than 15 years of management experience in biotechnology and healthcare environments, Ms. Maderis possesses a diverse portfolio of ...

The FINANCIAL — Sanofi and its subsidiary Genzyme announced that new magnetic resonance imaging (MRI) data from the Lemtrada (alemtuzumab) clinical development program will be presented today at the ...